Veraxa Biotech Holding AG — Form F-1
Filed July 31, 2026 · analyzed by the Registration Agent
F-1
— Neutral
significance 28/100
What the filing says
Veraxa Biotech Holding AG is conducting an IPO via Form F-1, with auditor consents filed July 31, 2026. WithumSmith+Brown audited Voyager Acquisition Corp. (the SPAC) as of December 31, 2025–2024, noting going-concern risk; Grassi audited Veraxa Biotech AG (operating entity) for fiscal 2025–2024 and Veraxa Biotech Holding AG (parent, inception June 25, 2025 through December 31, 2025). No financial metrics, deal size, or transaction terms are disclosed in these consent exhibits alone.
Why this rating
These are boilerplate audit consents required for IPO filing. Going-concern flag signals financial stress but is routine for SPACs. No material dollar amounts or deal specifics stated.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.